Trial Profile
Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Jun 2012 Actual patient number 51 added as reported by ClinicalTrials.gov.
- 20 Jun 2012 Actual end date (1 Mar 2012) added as reported by ClinicalTrials.gov.
- 20 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.